'Pretty striking': Pfizer results prompt calls for Australian investment in new technology

  • 📰 smh
  • ⏱ Reading Time:
  • 18 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 80%

Business News News

Business Business Latest News,Business Business Headlines

Strong early results from Pfizer and BioNTech's phase 3 coronavirus vaccine trial have been welcomed by local vaccine experts, promoting renewed calls for Australia to invest in new types of vaccine manufacturing technology | MsEmmaK

She warned there were still key unknowns about the results, however, including how long the protection against the virus might last and whether some cohorts of trial participants may not be seeing benefits from the vaccine.

The Pfizer product, known as BNT162b2, has already been granted a provisional determination by Australia's Therapeutic Goods Administration, which paves the way for Pfizer to apply for a provisional registration of the product.and began this process on Monday. CSL will also make the University of Queensland's vaccine if it passes trials.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

MsEmmaK Hang on, can you verify this story? Apparently 40K people with covid, 94 patients were chosen of which 8 received the vaccine (the others placebo). Before we start talking about a vaccine for billions of people let’s get a bit of perspective first.....

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 6. in BUSİNESS

Business Business Latest News, Business Business Headlines